Comparative Pharmacology
Head-to-head clinical analysis: FERNDEX versus SESQUIENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERNDEX versus SESQUIENT.
FERNDEX vs SESQUIENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferndex is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft.
SESQUIENT is a monoclonal antibody that binds to the IL-23 receptor, inhibiting IL-23-mediated signaling and subsequent activation of inflammatory pathways involved in psoriasis and psoriatic arthritis.
Adults: 100 mg orally three times daily.
Intravenous injection of 20 mg/m² body surface area once every 3 weeks.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; may be prolonged to 24-30 hours in elderly or patients with renal impairment (CrCl <30 mL/min).
12 hours (range 10-14 h); allows twice-daily dosing in most patients; prolonged in renal impairment
Primarily renal excretion as unchanged drug (60-70%) and glucuronide conjugates (15-20%); biliary/fecal elimination accounts for <10%.
Renal: 80% unchanged; Biliary/Fecal: 15% as metabolites; 5% other
Category C
Category C
Iron Supplement
Iron Supplement